新活素联合托拉塞米治疗慢性心衰加重患者的临床疗效分析  

Clinical efficacy analysis of Xinhuosu combined with tolasemide in the treatment of patients with exacerbation of chronic heart failure

作　　者：张秀秀 ZHANG Xiu-xiu(Department of General Internal Medicine,Xuzhou New Health Geriatric Hospital,Xuzhou 221005,China)

机构地区：[1]徐州新健康老年病医院综合内科,221005

出　　处：《中国现代药物应用》2023年第24期102-105,共4页Chinese Journal of Modern Drug Application

摘　　要：目的 探讨冻干重组人脑利钠肽(商品名:新活素)联合托拉塞米治疗慢性心力衰竭(心衰)加重患者的疗效。方法 按随机数字表将80例慢性心衰加重患者患者分成对照组和试验组,每组各40例。两组患者均接受心衰常规治疗,对照组在常规治疗基础上加用托拉塞米、多巴胺治疗,试验组在常规治疗基础上加用托拉塞米和新活素治疗。比较两组患者治疗前后症状、体征(呼吸困难、腹胀、肺部啰音、水肿)发生情况,心、肾功能[左室射血分数(LVEF)、氨基末端脑利钠肽前体(NT-proBNP)、血肌酐(Scr)],不良反应(低血压、电解质紊乱等)发生情况。结果 治疗后,试验组肺部啰音、水肿的发生率显著低于对照组(P<0.05),两组呼吸困难、腹胀的发生率比较,无明显差异(P>0.05)。治疗后,试验组患者LVEF(52.70±5.58)%高于对照组的(49.68±3.30)%, NT-proBNP(2394.10±607.09)pg/ml、Scr(95.05±45.57)μmol/L均低于对照组的(4007.20±643.34)pg/ml、(118.58±30.67)μmol/L(P<0.05)。两组低血压、电解质紊乱发生率比较,无明显差异(P>0.05)。结论 新活素联合托拉塞米治疗慢性心衰加重可改善患者临床症状,对患者心肾功能有益,且不良反应较少。Objective To discuss the efficacy of lyophilized recombinant human brain natriuretic peptide(trade name:Xinhuosu)combined with tolasemide in the treatment of patients with exacerbation of chronic heart failure.Methods A total of 80 patients with aggravation of chronic heart failure were randomly divided into control group and experimental group,40 in each group.Patients in both groups received conventional treatment for heart failure.On this basis,the control group was treated with torasemide and dopamine,and the experimental group was treated with torasemide and Xinhuosu.Both groups were compared in terms of symptoms and signs(dyspnea,abdominal distension,lung rales and edema)before and after treatment,cardiac and renal function[left ventricular ejection fraction(LVEF),N-terminal pro-brain natriuretic peptide(NT-proBNP),serum creatinine(Scr)],occurrence of adverse reactions(hypotension,electrolyte disturbance).Results After treatment,the incidence rates of pulmonary rales and edema in test group were significantly lower than those in control group(P<0.05),and there was no significant difference in the incidence rates of dyspnea and abdominal distension(P>0.05).There was no statistically significant difference in the incidence of dyspnea and abdominal distension between the two groups(P>0.05).After treatment,LVEF of(52.70±5.58)%in the experimental group was higher than that of(49.68±3.30)%in the control group;NT-proBNP of(2394.10±607.09)pg/ml and Scr of(95.05±45.57)μmol/L in the experimental group were lower than those of(4007.20±643.34)pg/ml and(118.58±30.67)μmol/L in the control group(P<0.05).There was no statistically significant difference in incidence of hypotension and electrolyte disturbance between the two groups(P>0.05).Conclusion Xinhuosu combined with torasemide in the treatment of exacerbation of chronic heart failure can improve the clinical symptoms of patients,beneficial to the patients'cardiac and renal function,and has less adverse reactions.

关 键 词：冻干重组人脑利钠肽 多巴胺 托拉塞米 慢性心力衰竭 

分 类 号：R541.6[医药卫生—心血管疾病]